Allegheny Health Network | Association Partnerships

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.

Nathan Bahary, MD, PhD, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.

In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.

For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Lisa B. Ercolano, MD, discusses the treatment of sarcomas in an era of molecular medicine.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Glofitimab is the first and only CD20xCD3 T-cell engaging bispecific antibody approved for the treatment of relapsed/refractory DLBCL.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.

In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.

Cyrus M. Khan, MD, discusses the most recent findings that show the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.

Yazan Samhouri, MD, discusses some of the current research that his team at AHN is working on.

In an interview with Targeted Oncology, Prerna Mewawalla discussed the role of bispecific antibodies in multiple myeloma treatment and options to consider before patients reach the relapsed/refractory setting.

In an interview with Targeted Oncology, John Nakayama, MD discussed 2 recently reported, practice-changing studies in endometrial cancer, and where the field is heading.

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.

Multiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy.

Gene G. Finley, MD, discusses some of the treatment options that have been used in the small cell lung cancer space, including intensive chemotherapies and targeted agents.

Encouraging results in melanoma have led experts to explore the gut microbiome in colorectal cancer.  The next hot topic in research may be the gut microbiome's role for the prevention, progression, and management of colorectal cancer.

Patrick Wagner, MD, director of complex general surgical oncology at AHN Cancer Institute, discussed the current state of important developments in treatment of gallbladder cancer.

Gene Finley, MD, discusses his hopes for the small cell lung cancer field and what he hopes research focuses on in coming years.

In an interview with Targeted Oncology™, Nathan Bahary, MD, PhD, discussed adapting to new therapy options and what the future holds for improving care for patients with cholangiocarcinoma.

Gene G. Finley, MD, discusses the challenges that community oncologists are facing with small cell lung cancer treatment.

Yazan Samhouri, MD, discusses his impressions of the TRIANGLE clinical trial presented at the 2022 American Society of Hematology Annual Meeting.

Gene G. Finley, MD, discusses how he envisions the treatment landscape of small cell lung cancer may evolve over the next 5-10 years.